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Abstract  
AIM: Aim was to detect Brain and Acute Leukemia, Cytoplasmic (BAALC) and ETS-related gene 
(ERG) expression in patients with acute myeloid leukemia (AML) as well as to study their biologic 
and prognostic impact on the disease outcome and survival. 
PATIENTS AND METHODS: The current study was carried out on 44 patients with denovo acute 
myeloid leukemia, as well as 44 age and sex matched controls. The quantitative real-time reverse 
transcription-polymerase chain reaction (RT-PCR) assay was performed for estimation of BAALC 
and ERG expression. 
RESULTS: The current study was carried out on 44 patients with denovo acute myeloid leukemia, 
as well as 44 age and sex matched controls. The quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR) assay was performed for estimation of BAALC and ERG 
expression. BAALC was expressed in 36 (81.82%) of AML cases versus 10 (22.72%) of the control 
group which was highly statistically significant (P < 0.001). While ERG was positive in 39(88.64%) 
of cases and 8(18.18 %) of controls and that was also highly statistically significant (P < 0.001).  
CONCLUSION: Further researches still needed to clarify the role of BAALC and ERG in the 
pathogenesis of leukemia and their importance as targets for treatment of AML. 
 
 
 
 
 
Introduction 
 
Acute myeloid leukemia (AML) is a 
heterogeneous disease with respect to clinical picture 
and therapeutic outcome, partly reflected by 
differences in molecular and cytogenetics [1-3]. 
Clonal cytogenetic abnormalities are one of 
the most important factors predicting clinical outcome 
in acute myeloid leukemia and are used to guide risk-
adapted treatment strategies [4-6]. Deregulated 
expression of genes coding transcription factors 
involved in cell proliferation, survival or differentiation 
is known to be implicated in the process of 
leukemogenesis [7-9]. Brain and acute leukemia, the 
cytoplasmic gene (BAALC) and ETS-related gene 
(ERG) are examples of these transcription factors [10- 
12]. 
The brain and acute leukemia, cytoplasmic 
(BAALC), which maps on chromosome 8 at 8q22.3, 
was originally observed in the neuroderm and its 
expression was reported as a hematopoietic 
precursor, such as the early hematopoietic cells of a 
cluster of differentiation 34+ [8]. BAALC expression 
was higher in bone marrow compared to blood. In 
addition, high levels of BAALC expression were 
present in leukemic blasts in subsets of acute 
lymphoblastic leukemia (ALL) and AML patients with a 
normal karyotype [13], it may act as an adverse 
prognostic factor through prompting proliferation and 
inhibiting apoptosis in leukemia cells [14].  
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BAALC gene is considered as a marker of 
early hematopoietic progenitor cells. High levels 
of BAALC expression were found in AML patients with 
trisomy 8, as well as in a subset of cytogenetically 
normal –AML(CN-AML) patients in which it was 
considered as a poor prognostic factor [15,16].The 
role of BAALC in leukemogenesis is not fully 
understood, but it was proposed that BAALC blocks 
myeloid differentiation [15].  
ERG gene, located on chromosome band 
21q22, belongs to the ETS family of transcription 
factors required for normal hematopoiesis. ERG plays 
an important role in early hematopoiesis and 
hematopoietic stem cell (HSC) maintenance [17].  
It is a transforming proto-oncogene that is 
expressed in stem cells and endothelial cells. It is 
frequently overexpressed in AML patients with 
complex karyotypes and amplification of chromosome 
21 [18]. 
 
The ERG gene has been found to be involved 
in atypical chromosomal rearrangements with 
alterations of the transcription factor in several 
cancers. Aberrant expression of full-length ERG 
protein has been found in acute myeloid leukemia and 
acute T-lymphoblastic leukemia [19, 20]. 
Chromosomal rearrangements driving the formation of 
EWS/ERG and FUS/ERG fusion proteins have been 
described in a subset of Ewing sarcoma [21, 22] and 
in acute myeloid leukemia [23, 24]. In acute leukemia, 
high ERG mRNA expression levels are an 
independent prognostic factor. Studies have 
demonstrated that increased ERG expression is 
associated with poor prognosis in cytogenetically 
normal AML [25] and in adult T-ALL [10].  
Most of the previous researches were 
concerned about levels and prognostic effect of 
BAALC and ERG in CN-AML patients while data 
about their incidence in AML and relation to cases 
with abnormal karyotype were lacking. 
We sought to determine the prognostic impact 
of the expression of BAALC and ERG in de novo AML 
patients. 
The objective of this study was to detect the 
incidence of BAALC and ERG in a group of denovo 
AML patients with abnormal karyotype in comparison 
to normal individuals, their levels and distribution 
among AML FAB subtypes as well as to study their 
impact on the disease outcome and reliability in 
detection of minimal residual disease in relation to the 
cytogenetic markers. 
 
 
Patients and Methods 
 
The current study was carried out on 44 
patients with denovo acute myeloid leukemia (AML), 
in the period between, July 2011 and July 2012 
among cases referred to nuclear medicine and 
oncology unit of Kasr Al Ainy School of medicine, 
Cairo University with follow-up period of 18 months, 
as well as 44 age and sex matched controls. They 
were patients suspected to have hypersplenism or 
idiopathic thrombocytopenia coming for BM aspirate. 
Cases were diagnosed according to WHO criteria 
[25]. The diagnosis of AML was based on 
morphological and phenotypic data. Subtypes 
according to the French– American–British 
classification were available for all the patients. 
 Patients were 21 males and 23 females. Age 
ranged from 21 to 65 years. The control group 
included 17 male and 27 females with no medical 
history of any type of cancer. Their ages ranged 
between 22 and 50 years. All patients and controls 
were analyzed for clinical and laboratory findings, 
including full history taking, clinical examination, 
routine laboratory investigations, LDH, abdominal 
ultrasound for detection of organomegaly and 
lymphadenopathy. The patients were subjected as 
well to cytochemical, immunophenotypic and 
cytogenetic analysis to confirm the diagnosis and to 
divide the patients into their subtypes. Local 
institutional research board approval as well as written 
informed consent was obtained from all the 
participants before including them in the study. 
 All patients included in the study were treated 
according to the protocol of the nuclear medicine and 
oncology department, Cairo University, using ongoing 
induction and consolidation regimens for treatment of 
adult AML cases.  
 Induction of remission: Patients were 
subjected to 7-3 protocol [26] for induction of 
remission: Novantrone: 12 mg/m
2
, IV on day 1and 3. 
ARA – C: 100 mg/m
2
, continuous IV infusion, from day 
l-7. If remission is not achieved, this protocol was 
repeated again. If no or minimal response, patients 
were shifted to high dose chemotherapy. Induction 
therapy for acute promyelocytic leukemia (PML) 
included oral administration of all-trans-retinoic acid 
(ATRA) 45 mg/m
2
/day until induces remission.  
 Consolidation [27]: High-dose ARA-C for 4 
cycles. ARA-C: 2g/m
2
, over 2 hour's infusions, every 
12 hours on days 1-4. Significant association to 
relapse-free survival and overall survival were 
estimated for studied genes at a median follow-up of 
18 months. 
 Complete remission (CR) was defined as 
recovery of morphologically normal BM and peripheral 
blood cells with white cell counts ≥ 1,500/L, and 
platelets ≥ 100,000/L, less than 5% BM blasts and no 
evidence of extramedullary leukemia. Relapse was 
defined by ≥ 5% BM or peripheral blood blasts, or 
development of extramedullary leukemia in patients 
with previously documented CR. Relapse-free survival 
(RFS) was measured from the date of CR until the 
date of relapse or death [28]. 
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 Collection and Processing Of Samples 
Gene expression was analyzed using 
quantitative real-time RT-PCR. Three ml of peripheral 
blood (of AML cases) and bone marrow samples (of 
control group) were collected on sterile 
ethelenediaminetetraacetic acid (EDTA) vacutainers. 
Mononuclear cells were enriched by Ficoll-Hypaque 
gradient and total RNA was extracted from freshly 
separated cells using Qiagen RNeasy mini spin 
column (RNeasy mini kit, Qiagen, Valencia, CA, USA) 
according to the manufacturer instructions. 
Quantitative real-time RT-PCR assay was 
performed for estimation of BAALC and ERG 
expression. BAALC and ERG mRNA expression 
levels were estimated from the corresponding gene-
specific calibration curves. The level GAPDH 
expression was measured for each sample using 
GAPDH standard curve. 
 
DNA Synthesis and Real-Time PCR 
Quantitation of BAALC and ERG mRNA 
Expression  
One microgram of the total RNA was 
transcribed into cDNA using random hexamers (High-
capacity cDNA kit; Applied Biosystems). An aliquot of 
the cDNA was used for quantitative PCR amplification 
by Gene Amp 7500 Sequence Detection System 
(Applied Biosystems), using 50 l reaction mix 
containing 5l cDNA, 25 l TaqMan Universal PCR 
master mix, 2.5l primer-probe mix using the following 
primers and probes: 
BAALC (F): 5'-GCCCTCTGACCCAGAAACAG-3', 
BAALC (R): 5'-'CTTTTGCAGGCATTCTCTTAGCA-3', 
BAALC Probe: FAM-5'-
CTCTTTTAGCCTCTGTGGTCTGAAGGCCAT-3'-
TMRA. 
ERG (F): 5'-AACGAGCGCAGAGTTATCGT-3', ERG 
(R): 5'-GTGAGCCTCTGGAAGTCGTC-3', ERG probe: 
FAM-5'-GGAGTACAGACCATGTGCGGCAGTG-3'-
TMRA 
GAPDH (F): 5'-GAAGGTGAAGGTCGGAGTC-3', 
GAPDH (R): 5'- GAAGATGGTGATGGGATTTC -3, 
GAPDH probe: FAM-5 
-CAAGCTTCCCGTTCTCAGCC-3'-TMRA and 17.5 l 
H2O. 
The thermal cycling conditions included: 10 
min at 95 ºC followed by 45 cycles of denaturation for 
15 min at 95ºC, annealing/extension at 60ºC for 1 min. 
A negative control (5 l water instead of cDNA) was 
included in every TaqMan plate. The results were 
presented as the relative quantification levels of 
BAALC and ERG in relation to the internal control 
GAPDH using the comparative cycle threshold (CT) 
method (2
-ΔΔ
CT). The cycle number difference e.g 
(ΔCT = GAPDH − BAALC), was estimated for each 
case then 2
-ΔΔ
CT was calculated.  
The threshold cycle data (Ct) and baselines 
were determined using auto settings. The relative 
quantification of BAALC and ERG expression was 
calculated using the comparative CT method (2–
ΔΔCT) where ΔΔCT is the difference of ΔCT value 
between leukemia and the control (ΔΔCT = ΔCT 
leukemia gene – ΔCT control gene), and ΔCT is the 
difference of CT value between the target (gene) and 
endogenous reference (GAPDH) gene (ΔCT = CT 
Target gene – GAPDH gene). 
 
Statistics 
A pre-designed SPSS (Statistical Package for 
Social Science Version 17) file was used for data 
entry and analysis. The following tests were used: 
both unpaired and paired t - test, with 95 % 
confidence intervals (95% CI), comparison of 
nonparametric quantitative data in two different 
groups using their mean rank performed by Mann–
Whitney (Z). Chi-square was used for comparison of 
qualitative variables. Patients with expression values 
greater than the median of all samples were classified 
as high BAALC expression. ERG overexpression was 
defined as transcript level greater than the 75
th
 
percentile of all measurements. Correlation between 
various variables was done using Pearson moment 
correlation equation for linear relation. P value less 
than 0.05 was considered statistically significant and 
less than 0.01 was considered highly statistically 
significant. 
No pre-study power calculation was 
performed. However, based on the number of 
subjects and controls included in this study, the 
sample size provides 95.5 % power to detect a 
minimal difference of 9.0% with an alpha level of 
0.05 . ”  
 
 
Results 
 
The present study was carried out on 44 
patients with denovo AML, as well as 44 age and sex 
matched controls. The clinical and demographic data 
of the studied groups revealed no statistically 
significant differences between the 2 studied groups. 
The results of immunophenotyping and cytogenetics 
were obtained from the main laboratory of Kasr Alainy 
hospital. We selected the cases of M2 with t (8; 21), 
M3 with t (15; 17), and M4 with inversion 16, and M5 
with t (9; 11). While cytogenetic results of M1 cases 
were not available. Twelve patients (27.2%) achieved 
complete remission following consolidation 
chemotherapy while 32 patients (72.8%) did not. The 
overall survival of the patients ranged between 2 and 
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18 months. Relapse-free survival ranged between 0 
and 18 months. 
BAALC was expressed in 36 (81.82%) of AML 
cases versus 10 (22.72%) of the control group which 
was highly statistically significant (P < 0.001). While 
ERG was positive in 39 (88.64%) of cases and 8 
(18.18%) of controls and that was also highly 
statistically significant (P < 0.001).The distribution of 
the positive cases among FAB subtypes were as 
follows: 
For BAALC gene positive cases, 14/17 
patients (82%) were M1, 5/7 patients (71%) were M2, 
9/10 patients (90%) were M3, 4/5 patients (80%) were 
M4, 4/5 patients (80%) were M5. 
For ERG gene positive cases, 16/17 patients 
(94%) were M1, 5/7 patients (71%) were M2, 10/10 
patients (100%) were M3, 4/5 patients (80%) were 
M4, 4/5 patients (80%) were M5. 
 The real-time results of the studied genes 
expressed as CT were summarized in Table 1. 
Table 1: Results of ΔCT of BAALC and ERG genes in patients 
and controls 
 Patients (44) Controls (44) P value 
 Range Mean ± SD Range Mean±SD  
BAALC 26 - 45.5 35 ± 3.8 37.8 - 49.5 42.1 ± 8.2 0.045 (S) 
ERG 32.7- 46.6 39.7 ± 2.6 39.8 - 42.6 41.8 ± 1.1 0.064 (NS) 
GADPH 26.9 - 46 32.6 ± 1.6 29.2 - 40.1 33.3 ± 3.4 0.65 (NS) 
 
 The lower values of CT in AML cases 
compared to CT values in controls mean higher levels 
of BAALC and ERG genes in the cases as the 
numerical value of the CT is inversely related to the 
amount of amplicon in the reaction.  
 Follow-up of the patients revealed 12 cases of 
CR and 32 with the unfavorable outcome; 17 showed 
partial recovery (PR), 8 cases relapsed and 7 patients 
died. 
 Correlations between BAALC and ERG genes 
expression and other prognostic factors and treatment 
outcome were summarized in Table 2. Highly 
significant correlation was detected between positive 
genes expression and the presence of bulky tumor 
and organomegaly. 
Table 2: Correlation between the results of BAALC and ERG 
genes expression and prognostic factors in patients 
 BAALC ERG 
r p r p 
Age 
Sex 
Organomegaly  
Presence of bulky tumor 
High LDH level 
0.06 
0.06 
0.56 
0.73 
0.03 
0.07 [NS] 
0.41 [NS] 
P < 0.001 [HS] 
P < 0.001 [HS] 
0.066 [NS] 
0.06 
0.08 
0.55 
0.63 
0.03 
0.07 [NS] 
0.34 [NS] 
P < 0.001 [HS] 
P < 0.001 [HS] 
0.08 [NS] 
 
The levels of each gene were expressed as 2
-
ΔΔ
CTi.e.number of fold increased above the mean 
level of the control group. Patients were divided into 
two groups according to these levels (high and low) as 
described previously in a statistic paragraph. BAALC 
levels median and range were 1479.8 (220.8-7550.2) 
for high levels group and 10.1 (0.13-54.9) for low 
levels group. While levels of ERG were 425.5 (27-
1985) and 2.44 (0.021-8.17) for high and low levels 
groups respectively. Association of BAALC and ERG 
expression levels with clinical characteristics were 
summarized in Table 3. 
Table 3: Association of BAALC and ERG expression levels with 
clinical characteristics 
 
 
BAALC expression 
(N = 36 patients) 
ERG expression 
(N = 39patients) 
 
-No 
-% 
 
-Age (years) 
Median  
Range 
 
-FAB classification 
M1 
M2 
M3 
M4 
M5 
 
-Leucocyte count 
Median 
Range 
 
-Hg level 
Median 
Range 
 
-Platelet count 
Median  
Range 
 
-BM blasts% 
Median 
Range  
 
-Response to 
treatment 
 
-Relapse-free 
survival 
Median(months) 
 
-Overall survival  
Median (months) 
High 
24 
66.7 
 
 
42 
20-62 
 
 
9 
3 
6 
3 
3 
 
 
21.9 
3.0 -32 
 
 
7.5 
3.1-8.5 
 
 
100 
30-110 
 
 
85 
22-98 
 
 
2 
 
 
 
3 
 
 
6 
Low 
12 
33.3 
 
 
44 
21-65 
 
 
5 
2 
3 
1 
1 
 
 
13.6 
3.2-24 
 
 
8 
5.2-10 
 
 
120 
36-130 
 
 
80 
21-90 
 
 
10 
 
 
 
16 
 
 
18 
 
P value 
 
 
 
 
 
0.65 (NS) 
 
 
 
 
 
 
0.54 (NS) 
 
 
 
0.03 (S) 
 
 
 
0.64 (NS) 
 
 
 
0.73 (NS) 
 
 
0.67(NS) 
 
 
 
0.03(S) 
 
 
 
P < 0.001 
[HS] 
 
P < 0.001 
[HS] 
High 
24 
61.5 
 
 
43 
20-58 
 
 
3 
9 
6 
3 
3 
 
 
22.4 
3.2 -32 
 
 
7.8 
3.0-7.4 
 
 
90 
32-100 
 
 
83 
21-96 
 
 
3 
 
 
 
3 
 
 
6 
Low 
15 
38.5 
 
 
48 
21-65 
 
 
2 
7 
4 
1 
1 
 
 
12.1 
3-20.5 
 
 
8.9 
6.1-10.0 
 
 
110 
36-135 
 
 
77 
20-89 
 
 
9 
 
 
 
16 
 
 
18 
P value 
 
 
 
 
 
0.76 (NS) 
 
 
 
 
 
 
0.59 (NS) 
 
 
 
0.02 (S) 
 
 
 
0.75 (NS) 
 
 
 
0.56 (NS) 
 
 
 
0.43 (NS) 
 
 
0.04 (S) 
 
 
 
P < 0.001 
[HS] 
 
P < 0.001 
[HS] 
  
There were statistically no significant 
differences between the 2 studied groups regarding 
the BAALC gene expression before and after 
treatment (P value=0.86) or the ERG gene expression 
before and after treatment (P value=0.75) (Table 4). 
Table 4: Results of BAALC and ERG expression in patients 
before and after treatment 
ERG BAALC  
low high low   high  
 
2.4 
0.02-8.2 
 
425.5 
27.3-1985.9 
 
10.2 
0.13-54.9 
 
1479.8 
220.7-7550.2 
 
Median  
Range  
 
The multivariate regression test had revealed 
that BAALC and ERG are independent risk factors for 
acute leukemia, because (Table5). Although we 
abolished the effect of bad prognostic factors (age > 
60 years, high serum LDH and WBC levels, high bone 
marrow blast percentage, presence of a bulky tumor), 
still high levels of these genes are associated with 
lower CR, RFS, and shorter OS.  
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Table 5: Multivariate regression analysis for BAALC and ERG 
expression with the prognostic markers 
 Patients groups OR HR 95% CI P value 
-Complete 
remission 
 
-RFS 
 
 
-OS 
BAALC expression,high versus low  
ERG expression, high versus low 
 
BAALC expression, high versus low 
ERG expression, high versus low 
 
BAALC expression, high versus low 
ERG expression, high versus low 
4.3 
3.9 
 
 
- 
- 
 
2.1 
1.5 
 
2.2 
2.8 
3.5-9.7 
3.1-8.5 
 
1.5-2.8 
1.1-2.7 
 
1.7-3.5 
2.4-4.5 
0.03 (S) 
0.04 (S) 
 
0.02 (S) 
0.02 (S) 
 
0.03 (S) 
0.04 (S) 
 
 
 
Discussion 
 
BAALC and ERG are transcription factors 
involved in the process of hematopoiesis 
subsequently their deranged expression is associated 
with leukemogenesis and its prognosis. We estimated 
their levels in BM of normal individuals and peripheral 
blood of leukemic cases as their expression is 
restricted to the progenitor cells in the BM and down-
regulated with cellular maturation. The present study 
revealed 36/44 (81.82%) BAALC positive AML cases 
compared to10/44 (22.72%) of the control group (P < 
0.001). While ERG was positive in 39 (88.64%) of 
cases and 8 (18.18 %) of controls and that was also 
highly significant (P < 0.001). Positive cases were 
associated with bulky tumor and organomegaly. That 
was higher than the incidence of BAALC detected by 
Balatzenko et al [29]; 53/91 (58.2%). 
High levels of BAALC and ERG were 
detected almost concomitantly in 54.5% of cases. 
They showed significant positive correlation to white 
cell counts. Marcucci et al. [19], also detected 
concomitant high BAALC and ERG levels in 25% of 
AML-NC cases with positive correlation to blast 
counts. 
Eid et al., [25], detected high expression of 
BAALC in 70% of patients and its expression did not 
correlate with the clinical parameters of patients. ERG 
was high in 33.3% of patients and its expression was 
associated with lower ages and higher white cell 
counts. 
The distribution of positive cases and cases 
with high BAALC and ERG among FAB subtypes did 
not show any significant difference. Subsequently, no 
association with their cytogenetic abnormalities was 
found. That was also concomitant with results of Eid 
et al, [25] but different from that of Baldus et al., 
2006[10] who found a significant association between 
BAALC and M0/M1.  
Heuser et al. [30] have shown that BAALC 
expression hinders cell differentiation, but does not 
promote cell proliferation. They believed that for the 
onset of leukemia another factor must exist to 
promote uncontrolled proliferation.  
As regard treatment outcome high levels of 
BAALC and ERG were associated with lower 
incidence of CR (P = 0.03 and 0.04 respectively) and 
shorter RFS and OS (P<0.001).  
Multivariable analysis demonstrated that 
BAALC and ERG genes over-expression are an 
independent predictor of low rate of CR, shorter RFS, 
and OS. These results are in consistent with Metzeler 
et al., 2009 [12], who found that high transcript levels 
of ERG and BAALC were predictors for inferior OS 
and a lower rate of CRs. They also described 
significant positive correlations between the 
expression levels of the two genes and a third one 
(MN1). In agreement with these results, Baldus et al. 
2003 [8], 2006 [10] demonstrated a significant 
association between high BAALC expression and 
resistance of AML to therapy and low CR. Moreover, 
they found high BAALC to be an independent 
predictor of relapse. Marcucci et al., 2005 [19] also 
demonstrated that increased ERG expression was 
associated with poor prognosis in CN-AML.  
Schwind et al., 2010 [31], found that 
expression levels of both BAALC and ERG were the 
only factors significantly associated with overall 
survival upon multivariable analysis.  
In order to investigate the applicability of 
BAALC and ERG in the detection of MRD, we 
measured their levels again in patients achieved CR 
for the first time. Although their levels decreased in 
each examined case but their reduction did not reach 
statistical significant difference while the cases 
showed normal morphological and cytogenetic 
examinations. 
Weber et al., [32] correlated BAALC 
expression levels of the diagnostic samples with those 
of the first sample showing complete molecular 
remission (CMR) defined by NPM1 mutational status. 
They found, no significant difference of BAALC 
expression levels in those nine patients during 
treatment. However, 13 patients with BAALC 
overexpression at diagnosis showed a strong 
reduction in its mean expression levels at first CMR. 
Moreover, in four cases a molecular relapse was 
detected based on elevated BAALC expression levels 
within 37–149 days before morphological relapse. 
Conflicting results had appeared when they correlated 
BAALC expression levels with other mutated genes 
used in MRD detection. 
Due to limited financial support, we could not 
estimate the changes in BAALC and ERG levels 
during the course of treatment and follow-up. Their 
levels might decrease gradually after CR. To 
overcome the previous conflicting results, larger scale 
researches must be done on AML cases to determine 
applicability and sensitivity of BAALC in the detection 
of MRD. 
As regard ERG, the levels in AML cases did 
not differ significantly from theirs in normal BM. So the 
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determination of cut-off value to detect MRD will not 
be applicable.  
Further researches still needed to clarify the 
role of BAALC and ERG in the pathogenesis of 
leukemia and their importance as targets for treatment 
of AML that could be promising due to their high 
incidence of expression in AML. 
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